Advertisements



Spark Therapeutics co-founder Dr. Katherine High takes C-suite role at North Carolina gene therapy company

In the wake of its potential $4 billion deal with Bayer, the firm is expanding its leadership team......»»

Category: topSource: bizjournalsJan 13th, 2021

Why Spark"s stock price is down 30 percent

Despite posting its first-ever profitable quarter, shares of Spark Therapeutics were trading down 30 percent Tuesday morning after the Philadelphia gene therapy company reported two patients had an adverse immune response to its experimental hemophilia.....»»

Category: topSource: bizjournalsAug 7th, 2018

Sell-Side Picks Top Gene Therapy Takeout Candidates Following Spark Therapeutics Deal

Roche Holdings AG Basel ADR (OTC: RHHBY)'s announcement regarding an agreement to acquire gene therapy company Spark Therapeutics Inc (NASDAQ: Latest Ratings fo.....»»

Category: blogSource: benzingaFeb 25th, 2019

Editas surges 50% as ARK founder Cathie Wood sees genomic stocks driving returns for the next 5 years

Behind Tesla, the third largest holding in the ARKK ETF is CRISPR Therapeutics, a gene editing company that makes up 5.7%.....»»

Category: topSource: businessinsiderDec 21st, 2020

NC"s Cellex gets green light from FDA for first coronavirus antibody test in US

A life sciences company based in North Carolina has received the first approval from the U.S. Food and Drug Administration for an antibody test for COVID-19, another laurel for the Research Triangle's role in combatting the global pandemic. On Thursday.....»»

Category: topSource: bizjournalsApr 6th, 2020

North Carolina wins 200-job project over California, Colorado

A genetics medicine company has picked Sanford over competing locations in California, Massachusetts and Colorado for a 209-job manufacturing facility. Audentes Therapeutics' Sanford site will be the second large-scale manufacturing operation for the C.....»»

Category: topSource: bizjournalsFeb 19th, 2020

Exclusive: Why this NC State grad brought his firm"s $654M in assets to Captrust

Raleigh-based Captrust’s latest buy is a North Carolina firm – a company that, according to its founder, wasn’t meant to be for sale......»»

Category: topSource: bizjournalsFeb 11th, 2020

Gene therapy invented at Nationwide Children"s lands $1.1B commercialization deal for Boston biotech

A gene therapy invented at Nationwide Children's Hospital just landed a licensing deal worth as much as $2.8 billion for a Boston biotech, and now the company's Columbus office will play a big role in getting the treatment to the market. Sarepta Th.....»»

Category: topSource: bizjournalsDec 24th, 2019

Roche to complete $4.3 billion Spark deal as regulators give all clear

Swiss drugmaker Roche plans to complete its $4.3 billion takeover of gene therapy specialist Spark Therapeutics on Tuesday after U.S. and British authorities ruled the deal would not hurt competition in hemophilia A treatment......»»

Category: topSource: reutersDec 17th, 2019

U.S. approves Roche"s $4.3 billion purchase of Spark Therapeutics

Swiss drugmaker Roche has won U.S. antitrust approval for its $4.3 billion deal to buy gene therapy specialist Spark Therapeutics clearing the way for the Swiss drugmaker's push into treating rare diseases including hemophilia A......»»

Category: topSource: reutersDec 16th, 2019

Medical linen provider to build second North Carolina plant

HandCraft Healthcare Linen & Uniform Specialists, which earlier this year opened its first North Carolina plant in High Point, has announced plans to open a second plant in the state in Wilson.  The Richmond, Virginia-based, family-owned company p.....»»

Category: topSource: bizjournalsDec 9th, 2019

Make it 10: Roche again extends $4.3B bid to buy Spark Therapeutics

For the 10th time this year, Roche has extended its $114.50 per share tender offer to Spark Therapeutics stockholders. In February, Roche of Basel, Switzerland, entered into an agreement to buy Philadelphia gene therapy pioneer Spark Therapeutics for $4.....»»

Category: topSource: bizjournalsDec 9th, 2019

Crispr"s Gene-Editing Therapy Found Effective In Treating Blood Disorders In Early-Stage Study

Crispr Therapeutics AG (NASDAQ: CRSP) shares are ripping higher after the company focused on developing gene therapies using its proprietary CRISPR/Cas9 platform said CTX001, a gene-editing therapy it's 0.....»»

Category: blogSource: benzingaNov 19th, 2019

FTC staff recommends approval of Roche deal for Spark: report

The Federal Trade Commission staff reviewing Roche's plan to buy U.S.-based gene therapy specialist Spark Therapeutics for $4.3 billion recommended that the deal be approved without requiring any asset sales, the Capitol Forum reported on Thursday......»»

Category: topSource: reutersOct 24th, 2019

In Bay Area exodus, Petaluma company heads to North Carolina

The apparel maker said the Bay Area's tight labor market and high housing costs sent the company to Appalachia......»»

Category: topSource: bizjournalsSep 6th, 2019

Gene therapy developer Gyroscope Technologies raises $60.6M

Gyroscope Therapeutics, a British gene therapy company that has its U.S. headquarters in Ambler, raised $60.6 million in a venture capital financing. The Series B round was led by Syncona Ltd., a previous backer that invested just under $58 milli.....»»

Category: topSource: bizjournalsSep 3rd, 2019

$4.3B deal delayed again: Roche extends Spark Therapeutics offer for sixth time

The slow-moving regulatory review process is once again being blamed for the latest delay in Roche’s proposed $4.3 billion acquisition of Philadelphia gene therapy pioneer Spark Therapeutics Inc. Roche said on Monday it is extending the offering per.....»»

Category: topSource: bizjournalsSep 3rd, 2019

Roche, Spark again extend $4.3 billion takeover offer

Roche Holding and Spark Therapeutics announced on Tuesday another extension of the Swiss drugmaker's $4.3 billion takeover offer for the U.S. gene therapy specialist as regulatory reviews continue......»»

Category: topSource: reutersSep 3rd, 2019

Catalent Analyst Cites Valuation Concerns In Downgrade

KeyBanc Capital Market's bull case for Catalent Inc (NYSE: CTLT) has come to an end. The company has taken the necessary steps to gain exposure to the high-growth biologics and gene therapy space, according to the.....»»

Category: blogSource: benzingaAug 28th, 2019

Sarepta says adverse event report for DMD gene therapy erroneously submitted

Sarepta Therapeutics Inc said on Thursday it was informed that an adverse event report was erroneously submitted to the U.S. health regulator regarding an ongoing study of the company's gene therapy for Duchenne muscular dystrophy (DMD)......»»

Category: topSource: reutersAug 8th, 2019

Sarepta stock drops on erroneous adverse event report to FDA

Sarepta Therapeutics Inc. shares fell Thursday after the gene therapy company said an adverse event report was sent to the Food and Drug Administration in error over a muscular dystrophy treatment. Sarept.....»»

Category: topSource: marketwatchAug 8th, 2019